Researchers at Emory University's Winship Cancer Institute have discovered a new type of immune cell that could help more patients to benefit from future immunotherapies. These "stem-like CD4 T cells" reside in lymph nodes near tumors and possess the potential to significantly boost anti-tumor immune response.
The study, published in Nature, reveals that these cells can self-renew and differentiate into various immune cell types. Characterized by the presence of PD1 and TCF1 proteins, these cells have shown the ability to enhance the effectiveness of PD1 blockade immunotherapy in laboratory models.
Dr. Haydn T. Kissick, the lead researcher, explains: "In around 10% of patients where the stem-like CD4 cell is active, there is a far more vigorous immune response to the cancer. These patients survive longer after surgery and are much more likely to respond to checkpoint immunotherapy. However, the challenge we identified is that in most patients, this cell remains in a suppressive state, which essentially tells the immune system to remain idle and ignore the tumor.”
Search Antibodies Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.
The research team found that nearly all patients have these stem-like CD4 T cells in their tumor-adjacent lymph nodes. Maria Cardenas, the study's first author, emphasizes the cells' potential: "While finding the immune system of patients with cancer in this idle state is common, we discovered that the stem-like CD4 T cell is capable of switching to an active state. It can restart a powerful anti-tumor immune response and enhance responsiveness to PD1 blockade in animal models.”
This discovery opens up new avenues for cancer treatment, particularly for patients who don't respond to current immunotherapies. The researchers are now exploring ways to activate these cells and maintain their anti-tumor response, with plans to utilize mRNA and lipid nanoparticle technology to reprogram the cells.
While challenges remain, Dr. Kissick is optimistic about the potential of this research: "We have all the pieces of the puzzle here, it’s just a matter of putting them together."